Kymira Therapeutics Third Quarter 2026 Results Call - KYMERA THERAPEUTICS INC

Financial Performance:

• Revenue: No collaboration revenue recognized in Q3 2026; remaining 2026 collaboration revenue expected to be zero as milestones were recognized in Q2.
• Operating Expenses: Reported R&D expenses were $128.5 million (excluding $10.9M stock-based compensation), an 8% increase QoQ; Reported G&A was $18.7 million (excluding $7.9M stock-based compensation), an 14% decrease QoQ to $10.8 million in adjusted cash G&A.
• Cash Position: Ended September 2026 with $1.6 billion in cash, cash equivalents, and investments, providing a runway into 2029.
• Capital Allocation: Funds sufficient to complete KT621 Phase 2b, advance KT579 to Phase 1b, and fund initial KT621 Phase 3 studies in AD and early asthma development without external financing.

Guidance and Future Outlook:

• KT621 (Atopic Dermatitis): Phase 2b data expected by year-end 2026; Phase 3 study initiation planned for mid-2027, contingent on data and FDA alignment.
• KT621 (Asthma): BREATH Phase 2b top-line results expected in late 2027.
• KT579 (Lupus): Advancement to Phase 1b "Lumora" trial in patients expected in early 2027; broader development strategy for IRF5 program to be disclosed next year.
• Pipeline: Sanofi advancing KT485 (IL4/13 degrader) in Phase 1; Gilead advancing KT200 (CDK2 molecular glue) to IND in 2027; research pipeline targeting one Development Candidate annually.
• Quiet Period: Company entering a quiet period next week ahead of STAT6 data; no new commentary on the program until data release.

Business Segments and Product Lines:

• KT621 (STAT6 Degrader): Oral candidate for atopic dermatitis (AD) and asthma; Phase 2b "Broaden 2" completed its 16-week placebo-controlled portion with 98% of eligible patients enrolled in the 52-week open-label extension.
• KT579 (IRF5 Degrader): Phase 1 healthy volunteer data showed robust IRF5 degradation (>90% in top 5 dose cohorts), functional modulation of inflammatory cytokines (87-94%), interferon response (98% inhibition), and B-cell biology.
• Safety Profile (KT579): Well-tolerated in healthy volunteers with a safety profile comparable to placebo; no serious adverse events or infection rate imbalances.
• Future Indications: KT579 being evaluated for potential expansion beyond lupus to Sjögren's, IBD, and RA based on genetic links and pathway modulation.

Market and Competitive Landscape:

• AD Market: Addresses 6-9 million US patients with moderate-to-severe AD, with only ~400,000 currently on advanced systemic therapies; aims to capture patients reluctant to use injectable biologics or drugs with boxed warnings.
• Market Dynamics: Market research indicates patients and prescribers prefer safe, effective oral therapies; precedent set by Tepezza and Ixekizumab demonstrates expansion of treated population despite lower efficacy than biologics.
• KT621 Positioning: Aims for efficacy comparable to Dupilumab at 16 weeks; positioned to treat comorbid Type 2 inflammatory conditions simultaneously.
• Competition: Focuses on expanding the market to untreated or poorly treated patients rather than solely competing on efficacy metrics against existing biologics.

Risks and Challenges:

• Regulatory/Development: Clinical success of Phase 3 programs remains contingent on Phase 2b readouts; cross-trial efficacy comparisons to biologics carry inherent methodological flaws.
• Market Adoption: Patient perception of disease severity and fear of biologics remains a key adoption barrier; must prove oral therapy safety and efficacy to overcome this.
• Trial Execution: High screen failure rates in asthma trials due to strict inclusion/exclusion criteria; potential for high placebo response rates in AD and Lupus trials.
• Safety Monitoring: Ongoing need to monitor for infection risks and potential mechanism-based safety signals (e.g., conjunctivitis for KT621) in future patient studies.

Management Commentary and Tone:

• Confidence: Management expressed high confidence in the platform's ability to translate preclinical data to humans, citing seven successful first-in-class degrader advancements.
• Tone: Optimistic and strategic; emphasized the "compounding" effect of learnings across programs and the unique value of oral, first-in-class degraders.
• Transparency: Acknowledged the difficulty of cross-trial comparisons but maintained a scientific expectation of KT621 efficacy aligning with Dupilumab; deferred specific dose selection details to maintain competitive advantage.

Analyst Questions and Answers:

• KT579 Phase 1b Design: Study will enroll both interferon-high and -low SLE patients; success criteria include recapitulating degradation and biomarker modulation in patients without ex vivo stimulation.
• KT621 Efficacy Expectations: Management reiterates the "ballpark" expectation of Dupilumab efficacy but refuses to provide specific numerical targets, noting the scientific and commercial value lies in the oral delivery profile.
• Dose Selection: Doses showing >90% degradation were selected; no specific dose announced for KT579 to avoid competitive intelligence; multiple options exist.
• Safety Specifics: KT579 degradation in skin was confirmed comparable to blood; for KT621, conjunctivitis is mechanistically expected, but data will be reviewed post-readout.
• Platform Capabilities: Confirmed focus on intracellular targets; extracellular degraders likely to be pursued only if they can be developed as oral agents.

Other Key Points:

• Market Expansion: Emphasis on KT621's potential to treat comorbidities (e.g., AD, asthma, EoE, CRS) as a single oral agent.
• Strategic Shift: Decision to delay disclosure of the next program introduction until next year to focus on upcoming major data releases.
• Trial Enrollments: KT621 AD study enrolled two quarters early due to high site/patient enthusiasm; KT579 Phase 1b will explore clinical outcome measures (SLEDAI, BILAG) alongside biomarkers.
• Catalysts: 2027 catalysts identified as KT621 Phase 3 initiation in AD and subsequent asthma data.